PRESS RELEASE published on 02/17/2024 at 01:50, 2 years 5 months ago BioNxt Solutions Finalizes Agreement BioNxt Solutions Inc. finalizes Settlement Agreement with a creditor to settle $282,415 debt through issuance of common shares and a cash payment. Debt to be settled in three instalments of shares based on market price Common Shares Debt Settlement BioNxt Solutions Inc. Settlement Agreement Creditor
PRESS RELEASE published on 01/30/2024 at 05:48, 2 years 6 months ago BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising gross proceeds of $288,000 to fund drug development and working capital purposes Private Placement Working Capital Investment Drug Development BioNxt Solutions Inc.
PRESS RELEASE published on 12/22/2023 at 09:05, 2 years 7 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/22/2023 at 01:50, 2 years 7 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/12/2023 at 09:05, 2 years 7 months ago BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
PRESS RELEASE published on 12/09/2023 at 04:30, 2 years 7 months ago BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
PRESS RELEASE published on 11/25/2023 at 01:44, 2 years 8 months ago Bionxt Solutions Announces Convertible Debenture and Interest Settlement
PRESS RELEASE published on 11/20/2023 at 09:05, 2 years 8 months ago BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
PRESS RELEASE published on 11/15/2023 at 09:05, 2 years 8 months ago BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
PRESS RELEASE published on 11/13/2023 at 09:05, 2 years 8 months ago BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
Published on 07/31/2026 at 01:39, 5 hours 39 minutes ago Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 7 hours 33 minutes ago Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 8 hours 17 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 8 hours 18 minutes ago Eagle Plains Announces Approval of Warrant Expiry Extension
Published on 07/30/2026 at 18:45, 12 hours 33 minutes ago First Canadian Graphite Reports High-Grade Graphite Prospecting Results up to 43.4% Cg at Lac Guéret South Project
Published on 07/31/2026 at 07:00, 18 minutes ago Medacta Group SA: Medacta reports continued above-market revenue growth of 9.7% in c.c. in H1 2026
Published on 07/31/2026 at 06:30, 48 minutes ago A successful first half of 2026 sets the stage for the second half
Published on 07/31/2026 at 06:30, 48 minutes ago Executing the strategy and strengthening the market position
Published on 07/31/2026 at 06:30, 48 minutes ago Strong first half with 11.5% organic growth in recurring EBIT, guidance upgraded
Published on 07/30/2026 at 18:15, 13 hours 2 minutes ago Publication of the 2026 half-year financial report
Published on 07/30/2026 at 18:00, 13 hours 18 minutes ago PR ICADE – ACQUISITION OF A CONTROLLING INTEREST IN COMET
Published on 07/30/2026 at 18:00, 13 hours 18 minutes ago GUILLEMOT CORPORATION: 2026 first-half turnover / Strong consumer demand and a second half with a strong lineup of major product launches
